Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2024 · 10-Q
Revenue$701.78M$701.78M+17.1% vs Q2 2023 Net Income$5.99M$5.99M−49.7% vs Q2 2023 EPS Diluted$0.02$0.02−75.0% vs Q2 2023 Gross Profit$249,947,000+13.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$39,657,000N/M Free Cash Flowderived$29,031,000N/M Margins · derivedGross margin35.6%−1.1 pt vs Q2 2023
Operating margin13.6%+0.2 pt vs Q2 2023
Net margin0.9%−1.1 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 9, 2024 · 40 d after period end